Drug intelligence / Profile preview

YJQ-101

Development stage: Preclinical
Lead developer: Hanwha Pharma
Modality: Small Molecules
Administration: Oral

Overview

YJQ-101 is an investigational drug candidate currently in the preclinical stage of development by Han Wha Pharma. It is being developed for the treatment of gastrointestinal (GI) tract system disorders. As the project is in the early research and formulation phase, specific details regarding its mechanism of action, biological targets, and chemical composition have not been publicly disclosed. It is categorized within the company's pipeline as a potential new drug or incrementally modified drug (IMD) targeting the digestive system.

Beyond the preview

Go deeper on YJQ-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YJQ-101.

Explore the full profile